Top 10 Companies in the (R)-1-Phenylbutylamine (CAS 1552284) Market (2026): Market Leaders Powering Global Pharmaceutical Synthesis

MARKET INSIGHTS

Global (R)-1-Phenylbutylamine (CAS 1552284) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 7.3% during the forecast period.

(R)-1-Phenylbutylamine is a chiral amine compound recognized by its CAS number 1552284, belonging to the class of optically active primary amines. As the (R)-enantiomer of 1-phenylbutylamine, it serves as a critical chiral building block and resolving agent in asymmetric synthesis. Its high enantiomeric purity makes it particularly valuable in pharmaceutical manufacturing, where stereochemical precision directly impacts drug efficacy and safety profiles.

The market is witnessing steady growth, primarily driven by rising demand for enantiopure intermediates in active pharmaceutical ingredient (API) synthesis and the broader expansion of the chiral chemicals industry. Furthermore, increasing R&D investments in asymmetric catalysis and green chemistry are reinforcing its commercial relevance. Key suppliers operating in this space include specialty fine chemical manufacturers across North America, Europe, and Asia-Pacific.

(R)-1-Phenylbutylamine (CAS 1552284) Market – View in Detailed Research Report

🔟 1. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: High-purity (R)-1-Phenylbutylamine for API synthesis and custom chiral chemistry

Merck KGaA leads the global chiral amine market with its advanced catalytic processes and robust production capacity. The company supplies high‑purity intermediates to major pharmaceutical manufacturers, enabling the development of CNS‑active drugs and oncology therapeutics.

Sustainability Initiatives:

• Investing in green chemistry to reduce carbon footprint
• Developing scalable enzymatic synthesis routes
• Commitment to circular economy via waste reduction
• Partnerships with pharma for single‑enantiomer drug development

---

9️⃣ 2. Tokyo Chemical Industry (TCI)

Headquarters: Tokyo, Japan
Key Offering: Advanced catalytic synthesis of (R)-1-Phenylbutylamine for fine chemicals and pharmaceuticals

TCI provides state‑of‑the‑art asymmetric synthesis solutions, ensuring high enantiomeric excess and purity for API intermediates. Its strong R&D pipeline supports the growing demand for chiral building blocks in drug discovery.

Sustainability Initiatives:

• Advanced catalytic processes for higher enantiomeric excess
• Utilization of renewable energy in manufacturing
• Collaborations with universities for green chemistry research
• Focus on reducing hazardous waste generation

---

8️⃣ 3. Enamine

Headquarters: Kyiv, Ukraine
Key Offering: Agile custom synthesis of (R)-1-Phenylbutylamine for R&D and scale‑up projects

Enamine’s flexible manufacturing platform allows rapid production of chiral intermediates for academic and industrial research, supporting the development of novel therapeutics.

Sustainability Initiatives:

• Eco‑friendly synthesis routes with reduced solvent use
• ISO 9001 and GMP certification for quality assurance
• Collaborations with biotech startups for green process development
• Continuous improvement in energy efficiency

---

7️⃣ 4. Biosynth

Headquarters: Basel, Switzerland
Key Offering: High‑purity (R)-1-Phenylbutylamine for pharmaceutical intermediates and custom synthesis

Biosynth leverages its expertise in chiral chemistry to provide premium quality intermediates for drug discovery programs worldwide.

Sustainability Initiatives:

• Investment in catalytic process optimization for lower energy use
• Commitment to REACH compliance and reduced toxicity
• Partnerships with academic research labs for green chemistry
• Implementation of waste minimization strategies

---

6️⃣ 5. Hairui Fine Chemicals Co., Ltd.

Headquarters: Shenzhen, China
Key Offering: Scalable production of (R)-1-Phenylbutylamine for global pharmaceutical supply chains

Hairui Fine Chemicals offers cost‑effective, high‑purity chiral intermediates, supporting the rapid expansion of pharmaceutical manufacturing in Asia‑Pacific.

Sustainability Initiatives:

• ISO 14001 environmental management system
• Low‑cost, high‑purity processes with minimal waste
• Use of green solvents and renewable feedstocks
• Continuous improvement in energy efficiency

---

5️⃣ 6. Apollo Scientific

Headquarters: Cambridge, United Kingdom
Key Offering: Specialty chiral reagents for pharmaceutical R&D

Apollo Scientific provides high‑quality chiral building blocks, enabling the synthesis of complex molecules for drug discovery and development.

Sustainability Initiatives:

• Sustainable sourcing of raw materials
• Continuous improvement in process efficiency
• Partnerships with pharma R&D for green chemistry
• Reduction of hazardous waste streams

---

4️⃣ 7. Synthonix Inc.

Headquarters: Boston, USA
Key Offering: Innovative chiral catalysts and (R)-1-Phenylbutylamine for API synthesis

Synthonix delivers cutting‑edge catalytic solutions that enhance yield and enantiomeric purity for pharmaceutical intermediates.

Sustainability Initiatives:

• Investment in process automation to reduce energy use
• Focus on green catalyst development
• Collaboration with CROs for sustainable synthesis
• Waste minimization and resource recovery

---

3️⃣ 8. Capot Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: High‑purity (R)-1-Phenylbutylamine for fine chemical and pharmaceutical applications

Capot Chemical supplies premium chiral intermediates, supporting both large‑scale production and custom synthesis projects.

Sustainability Initiatives:

• ISO 9001 quality management system
• Eco‑friendly packaging and logistics
• Commitment to waste minimization
• Use of renewable energy in production

---

2️⃣ 9. J&H Chemical

Headquarters: Shanghai, China
Key Offering: Custom synthesis of (R)-1-Phenylbutylamine for niche pharmaceutical projects

J&H Chemical specializes in small‑batch, high‑purity chiral intermediates, catering to academic and industrial research needs.

Sustainability Initiatives:

• ISO 14001 environmental compliance
• Green chemistry practices in synthesis
• Partnerships with universities for R&D
• Energy‑efficient manufacturing processes

---

1️⃣ 10. Ningbo Inno Pharmchem Co., Ltd.

Headquarters: Ningbo, China
Key Offering: Rapid scale‑up of (R)-1-Phenylbutylamine for pharmaceutical intermediates

Ningbo Inno Pharmchem delivers high‑purity chiral building blocks with fast turnaround, supporting global pharma supply chains.

Sustainability Initiatives:

• ISO 9001 certification for quality assurance
• Eco‑friendly synthesis routes with reduced solvent use
• Collaboration with global pharma partners
• Continuous improvement in waste reduction

---

Download FREE Sample Report: View Sample Report
Get Full Report: Download Full Report

Outlook

The (R)-1-Phenylbutylamine (CAS 1552284) market is projected to maintain robust growth, driven by escalating demand for enantiopure intermediates in API synthesis and the expansion of the chiral chemicals industry. Key growth drivers include rising R&D investments in asymmetric catalysis, green chemistry initiatives, and the increasing prevalence of single‑enantiomer drugs. The market is expected to achieve a CAGR of 7.3% from 2025 to 2034, reaching USD 52.7 million by 2034.

Future Trends

Emerging trends shaping the market include advancements in enzymatic resolution technologies, continuous flow synthesis, and the adoption of green chemistry practices. The peptide therapeutics segment is expected to grow rapidly, providing new opportunities for (R)-1-Phenylbutylamine as a key scaffold in GLP‑1 agonists and other peptide‑based drugs. Additionally, the expansion of CNS disorder treatments in emerging economies such as India and Brazil will further drive demand. Strategic licensing of novel catalytic processes is likely to capture additional market share, positioning early movers to achieve 15‑20% growth beyond the current CAGR.